Risk factors that increase recurrence in borderline ovarian cancers

Ozer Birge; Mehmet Sait Bakır; Ceyda Karadag; Can Dinc; Selen Doğan; Hasan Aykut Tuncer; Tayup Simsek

Risk factors that increase recurrence in borderline ovarian cancers

Am J Transl Res. 2021 Jul 15;13(7):8438-8449. eCollection 2021.

Authors

Ozer Birge¹, Mehmet Sait Bakır¹, Ceyda Karadag¹, Can Dinc¹, Selen Doğan¹, Hasan Aykut Tuncer¹, Tayup Simsek¹

Affiliation

¹ Akdeniz University, Department of Gynecology Obstetrics, Division of Gynecologic Oncology Antalya, Turkey.

PMID: 34377341
PMCID: PMC8340170

Abstract

Objective: In this study, we aimed to compare the clinical and pathological results of borderline ovarian tumor cases that were operated on in our clinic within the last 15 years and to investigate the factors affecting recurrence.

Materials and methods: The archived files of the patients with borderline ovarian tumors, who had been operated on at the Akdeniz University Medical Faculty Gynecological Oncology Unit between 2006 and 2020 were retrospectively reviewed. A total of 48 cases were identified and included in the study. Oncological results affecting relapse were evaluated using univariate and multivariate analysis models. Disease-free survival was assessed using the Kaplan-Meier method.

Results: The median follow-up period of the 48 patients included in our study was 51.5 months and while the shortest follow-up was 2 months, the longest follow-up period was 164 months. The mean age of the patients was 47.6 ± 12.5 years, and the mean BMI was found to be 27.2 ± 3.7. Of the patients, 19 (39.6%) were post-menopausal, and when all stages were included, the 10-year progression free survival (PFS) was 65%, while the 10-year overall survival (OS) was 96.6%. It was observed that 8 (16.6%) patients encountered recurrence during their follow-up. The multivariate analysis of significance found for the operation type, adjuvant chemotherapy and micro-invasion in the univariate analysis of clinical pathological characteristics with regard to recurrence, fertility-sparing surgery and micro-invasion were determined to have a significant difference in recurrence (p: 0,016, p: 0,048).

Conclusion: Borderline ovarian tumors are especially seen in young patients and although their clinical prognosis is very good, a significant difference was found in recurrence in patients who had undergone fertility-sparing surgery, in whom the micro-invasion was positive and in those receiving adjuvant chemotherapy, and disease-free survival was shorter in these patients and close follow-up of these patients is recommended.

Keywords: Borderline ovarian tumors; adjuvant chemotherapy; atypical proliferation; fertility-sparing surgery; recurrence; stromal invasion.